Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydromorphone + dexmedetomidine
- Development stage
- Phase 4
- Lead developer
- Orion
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Hydromorphone + dexmedetomidine is a drug combination used for premedication in anesthesia protocols. This combination provides sedation, analgesia, and facilitates subsequent treatments or interventions. Hydromorphone is an opioid that blocks pain signals in the brain, while dexmedetomidine is a highly selective alpha-2 agonist that provides sedation. When combined, they produce neuroleptanalgesia with synergistic effects that allow for lower doses of each drug to be used while providing effective sedation and analgesia.
- Other names
- HD treatment
02
Targets
ADRA1A (α1A)ADRA2B (α2B)ADRA2C (α2C)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)ADRA2A (α2A)
Beyond the preview
Go deeper on hydromorphone + dexmedetomidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydromorphone + dexmedetomidine.